The future is ORA®

The globally recognised oral vehicle product line brought to you exclusively by Medisca*



Trusted by healthcare professionals for compounded medications





A solution for many patients



Not everyone can swallow a pill. Some struggle with taste. Others need alternatives free from allergens or unnecessary ingredients. Whether it's a child, an elderly patient, someone with swallowing difficulties, or even a pet, medication should be easier to take — without compromising on effectiveness.

That's where ORA® comes in. Designed to help pharmacists create smooth, stable, and palatable liquid compounds, ORA ensures that patients — human and animal alike — get the treatment they need in a form they can take.

For our furry companions, ORA vehicles can be flavoured to suit a pet's taste, making medication more palatable and helping improve compliance for both oral and G-tube administration. Whether it's for a child, senior, or animal, ORA helps create customised, reliable solutions that make taking medication a little bit easier.

Did you know?

9% of school-aged children struggle to swallow tablets or pills, and 30 – 60% of geriatric patients experience symptoms of dysphagia. Additionally, pets often face challenges when taking pills, which is why liquid formulations are so important in veterinary care. Yet, oral tablets and pills remain the most widely available dosage form. ORA® offers a versatile alternative to ensure effective medication delivery for patients of all kinds.

Why pharmacists trust ORA®

Efficient, reliable compounding

ORA is developed to simplify and accelerate the compounding process, with published studies supporting its role in maintaining formulation stability and consistency.

Time-saving

Ready-to-use vehicles eliminate the need for additional suspending agents or flavour enhancers, reducing preparation time.

· Consistent results

Uniform dispersion from the first to the last drop.

Broad API compatibility

Successfully used in thousands of formulations, ensuring adaptability across therapeutic specialities.

Enhanced workflow efficiency

Reduces variability in compounding, minimising errors and improving overall productivity.

Trusted stability

Potency and effectiveness are essential in every compounded formulation. With over 150 studies conducted using commonly compounded APIs, ORA offers data-backed support for compatibility and stability.

Suspension integrity

Prevents active ingredient settling, ensuring uniform dosing.

Validated by science

Stability-tested across a range of active pharmaceutical ingredients (APIs).

· Reliable storage stability

Extended shelf-life supports efficient inventory management and reduces waste.

Optimised for patient adherence and satisfaction

Patients depend on you to provide effective, palatable, and easy-to-administer medications. ORA helps improve patient compliance.

Enhanced taste and texture

Pre-flavoured options increase palatability, improving adherence.

Alternative administration

Ideal for paediatric, geriatric, and veterinary* patients who have difficulty swallowing pills.

Customisable and versatile

Sugar-free, dye-free, and alcohol-free options cater to patients with specific needs.

Proven safety profile

Developed with high-quality ingredients to ensure patient safety and minimise potential allergens.



*It is recommended for the veterinarian and pharmacist to assess the ingredients to ensure the product is suitable for the specific patient. It is also important to note that ingredients such as parabens found in ORA may cause toxicity with longer term exposure in felines. Therefore, it should be considered for short term use only.



Discover the full ORA® product line



Sugar sensitivities shouldn't stand in the way of effective compounding. ORA-Blend® SF delivers the same reliable performance as ORA-Blend but without the sugar. It combines the stable suspending power of ORA-Plus® with the pleasant citrus-berry taste of ORA-Sweet® SF, making it easier to prepare oral suspensions that support adherence across all patient groups. Buffered and easy to shake, it's a thoughtful solution for patients who need a little extra care.

Compounding oral suspensions should be straightforward, for both the pharmacist and the patient. ORA-Blend® brings together the reliable suspending properties of ORA-Plus® with the palatability of ORA-Sweet®, offering a ready-to-use solution that simplifies preparation and enhances taste with its citrus-berry flavour. Buffered to a slightly acidic pH for stability and designed with patient adherence in mind, it's an ideal choice for paediatric and geriatric care.

Taste can be the difference between a dose taken or missed. ORA-Sweet® is thoughtfully formulated to support the creation of palatable oral preparations, with a balanced blend of sweetness and citrus-berry flavour. Its smooth texture, slightly acidic pH, and reliable flow help protect ingredient integrity while ensuring ease of use. ORA-Sweet is often paired with a suspending agent, like ORA-Plus®—to create stable, flavour-forward preparations for paediatric and geriatric

ORA-Sweet® SF offers a sugar-free solution for creating palatable, patient-friendly oral preparations. With a delicate balance of sodium saccharin for sweetness and a citrus-berry flavour blend, it enhances the taste of compounded formulations. Its smooth texture helps ensure easy flow and stability. Buffered to a slightly acidic pH, it helps preserve the integrity of most medicinal agents. Often mixed with other agents, ORA-Sweet SF maintains its flavour when diluted up to 50%, making it an ideal choice for paediatric and geriatric suspensions.





ORA-Plus®

Suspending Vehicle Véhicule de suspension

DESCRIPTION: ORA-Plus® is a unique suspending vehicle ideally suited for use in the preparation of oral, non-soluble (suspended), aqueous days forms. It is a buffered, bland whiche containing an antifloam agent and suitable prevarvatives. ORA-Plus® is buffered to an acidic pH to provide a vehicle which is consistent and predictable for extemporaneous compounding needs.

compounding needs.

DESCRIPTION: ORA-Plus⁶⁰ est un véhicule de suspension unique qui convient parfairement à la confection de préparations posologiques aqueuses orales et non solubles (suspensions). ORA-Plus⁶⁰ contient un agent amimousse et des agents de conservation appropriés. ORA-Plus⁶⁰ est amponde au pri acide pour servir de véhicules stable et fiable et pour répondre aux besoins relatifs à la fabrication des préparations extemporanées.

473 mL Padagis...

When consistency matters, ORA-Plus® delivers. Designed to support the compounding of smooth, stable oral suspensions, ORA-Plus blends science and practicality. Its gel-like matrix helps keep particles suspended with minimal settling, while a slightly acidic pH supports ingredient stability. Buffered and easy to shake, ORA-Plus is versatile enough to be used alone or combined — especially with ORA-Sweet® — to meet the needs of paediatric, geriatric, veterinary, and naso-gastric preparations.

Scientific research and studies behind ORA®

Backed by over **150 studies** using commonly compounded APIs, ORA is trusted by hospitals and listed in formulary databanks across North America. View a list of studies and explore the data that supports its role in consistent, reliable compounding.





Did you know?

ORA can be sold for home care, allowing patients to mix their medications with the oral vehicle in the comfort and convenience of their own home.

ORA® for paediatric care

The ORA line provides a trusted, patient-friendly solution for compounding paediatric oral liquid medications. These vehicles not only enhance taste but also ensure smooth and easy oral administration. Research on ORA vehicles highlights their potential to support stability in compounded suspensions, with specific formulations retaining at least 90% potency over 60 days when stored appropriately. The inclusion of sweeteners and flavours improves patient acceptance, making it easier for children to take their medication and helping to foster better adherence. With ORA, healthcare providers gain a reliable and effective tool to meet the unique needs of paediatric patients, ultimately improving both treatment outcomes and patient satisfaction.

Highlighted studies*

API	Base	Studies & Storage at RF*	Studies & Storage at RT*	Link
Acetazolamide	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	60 days	60 days	1
Aprepitant	Ora-Blend	111 days	111 days	7
Captopril	Ora-Sweet:Ora-Plus	14 days	7 days	7
	Ora-Sweet SF:Ora-Plus	10 days	5 days	1
Clonidine Hydrochloride	Simple Syrup, NF	28 days	N/A	7
Melatonin	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	N/A	90 days	7
Metronidazole	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	60 days	60 days	7
Ondansetron Hydrochloride	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	42 days	N/A	N
Phenobarbital	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	N/A	115 days	N
Verapamil Hydrochloride	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	60 days	60 days	7
Ziprasidone Mesylate	Ora-Sweet:Sterile Water for Injection	42 days	14 days	7
Zonisamide	Methylcellulose 0.5% w/v Solution	28 days	7 days	7

Featured formulas

F010378 Acyclovir 200 mg per 5 mL Oral Liquid F010379 Ondansetron 2 mg per mL Oral Liquid F010380 Omeprazole 2 mg/mL Oral Liquid

^{*}This data is provided for informational purposes only, representing the results of a study of the product stability with various active pharmaceutical ingredients. For further information on packaging, please refer to the publication link. This document does not serve, and may not be construed, as a representation or guarantee of product performance. In all cases, the practitioner is advised to consult recognised pharmaceutical compendia and other recognised sources for product formulation and other product characteristics, including stability. Medisca and it is affiliates make no warranties or representations with regards to the functioning or appropriateness of this product in any compounded formulation, the use of which is solely at the discretion and liability of the practitioner. It is the responsibility of the pharmacist or other appropriately state licensed professional to verify the accuracy and validity of the information contained herein, with regards to scheduling, federal and state/provincial laws allowing the use of the formulas, products and final compounds in the country of use. To the best of our knowledge, no AET (USP-51) results have been made available for these compounded formulations. It is recommended to refer to the study publication for more information about API source (i.e. tablet, capsule, powder), container closure and stability information.

ORA® for geriatric care

The ORA line delivers a reliable, palatable solution for compounding medications for geriatric patients. With seamless dispensing options for both oral administration and G-tubes, ORA ensures a simple and comfortable medication experience. ORA vehicles are designed to support stability, as demonstrated in various stability-indicating studies where specific formulations maintained potency for up to 60 days under proper conditions. Their versatility supports a wide range of formulations, offering flexibility to meet diverse patient needs. By enhancing taste, ORA improves medication acceptance and promotes better compliance. Consistent quality guarantees accurate dosing, making ORA a trusted and effective choice for geriatric medication compounding.

Highlighted studies*

API	Base	Studies & Storage at RF*	Studies & Storage at RT*	Link
Azathioprine	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	60 days	60 days	7
Baclofen	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	60 days	60 days	7
Clonazepam	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	60 days	60 days	7
Hydralazine Hydrochloride	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	1-2 days	Not stable	7
Labetalol Hydrochloride	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	60 days	60 days	7
Metoprolol Tartrate	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	60 days	60 days	7
Nifedipine	Ora-Sweet:Ora-Plus / 1% Methylcellulose: Simple Syrup, NF	91 days	91 days	7
Spironolactone	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	60 days	60 days	7
Sotalol	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	84 days	84 days	7
Tadalafil	Ora-Sweet:Ora Plus	N/A	91 days	7
Valacyclovir	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	14 days	N/A	7

Featured formulas

F010375 Topiramate 25 mg/5 mL Oral Liquid F010376 Metoprolol Tartrate 25 mg/mL Oral Liquid F010377 Allopurinol 20 mg/mL Oral Liquid

^{*}This data is provided for informational purposes only, representing the results of a study of the product stability with various active pharmaceutical ingredients. For further information on packaging, please refer to the publication link. This document does not serve, and may not be construed, as a representation or guarantee of product performance. In all cases, the practitioner is advised to consult recognised pharmaceutical compendia and other recognised sources for product formulation and other product characteristics, including stability. Medisca and its shiftliates make no warranties or representations with regards to the functioning or appropriateness of this product in any compounded formulation, the use of which is solely at the discretion and liability of the practitioner. It is the responsibility of the pharmacist or other appropriately state licensed professional to verify the accuracy and validity of the information contained herein, with regards to scheduling, federal and state/provincial laws allowing the use of the formulas, products and final compounds in the country of use. To the best of our knowledge, no AET (USP-51) results have been made available for these compounded formulations. It is recommended to refer to the study publication for more information about API source (i.e. tablet, capsule, powder), container closure and stability information.

ORA® for veterinary care

The ORA line provides a versatile, palatable solution for compounding oral liquid medications. Studies show that medications compounded with ORA vehicles maintain stability, ensuring accurate dosing for veterinary care. For example, alprazolam compounded with ORA-Sweet® and ORA-Plus® retains over 90% of its potency after 60 days under proper storage conditions. With the possibility to customise with veterinary flavours to suit each animal's taste preferences, ORA enhances palatability and promotes better patient compliance. Known for its consistent quality and performance, ORA is commonly used in veterinary compounding. Use should be guided by the prescriber and pharmacist, who are responsible for reviewing ingredient suitability for each animal.

Highlighted studies*

API	Base	Studies & Storage at RF*	Studies & Storage at RT*	Link
Amlodipine Besylate	Ora-Sweet:Ora-Plus / 1% Methylcellulose: Simple Syrup, NF	91 days	56 days	7
Aprepitant	Ora-Blend	111 days	111 days	7
Benazepril Hydrochloride	Ora-Sweet:Ora-Plus	30 days	N/A	7
Cisapride	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	60 days	60 days	7
Gabapentin	Ora-Sweet:Ora-Plus	91 days	56 days	7
Itraconazole	Ora-Sweet:Ora-Plus	56 days	56 days	7
Metronidazole	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	60 days	60 days	7
Ondansetron Hydrochloride	Ora-Sweet:Ora Plus / Ora-Sweet SF:Ora Plus	42 days	N/A	7
Oseltamivir	Ora-Sweet SF	35 days	35 days	7
Sildenafil	Ora-Sweet:Ora-Plus / 1% Methylcellulose: Simple Syrup, NF	91 days	91 days	7
Tramadol	Ora-Sweet SF:Ora-Plus / Ora Plus:Strawberry Syrup	90 days	90 days	7

Featured formulas

F010372 Sucralfate 200 mg/mL Oral Liquid
F010373 Chloramphenicol 150 mg/mL Oral Liquid
F010374 Fludrocortisone Acetate 0.5 mg/mL Oral Liquid

^{*}This data is provided for informational purposes only, representing the results of a study of the product stability with various active pharmaceutical ingredients. For further information on packaging, please refer to the publication link. This document does not serve, and may not be construed, as a representation or guarantee of product performance. In all cases, the practitioner is advised to consult recognised pharmaceutical compendia and other recognised pharmaceutical compendia in the recognised sources for product formulation and other product characteristics, including stability. Medisca and its affiliates make no warranties or representations with regards to the functioning or appropriateness of this product in any compounded formulation, the use of which is solely at the discretion and liability of the practitioner. It is the responsibility of the pharmacist or other appropriately state licensed professional to verify the accuracy and validity of the information contained herein, with regards to scheduling, federal and state/provincial laws allowing the use of the formulas, products and final compounds in the country of use. To the best of our knowledge, no AET (USP-51>) results have been made available for these compounded formulations. It is recommended to refer to the study publication for more information about API source (i.e. tablet, capsule, powder), container closure and stability information.

Precision in every dose

ORA® works seamlessly with our high-quality dispensing devices designed for precision, safety, and ease of use.





Formulation support and compounding services

Expert guidance to elevate your compounding practice Starting at just \$745/year

Gain access to the tools, knowledge, and personalised support needed to compound with confidence. From ORA-specific guidance to broader formulation assistance, our dedicated experts and expansive library are here to help you succeed.

Formulation assistance

- Instant access to a robust library of ORA® studies and stability information
- Explore over 10,000 formulations in the Medisca database
- Tailored recommendations for optimising ORA® preparations and more

On-demand compounding support

- Connect directly with experienced compounding professionals
- Receive personalised troubleshooting and technical advice
- Stay informed with regulatory insights and compliance support

Explore support packages designed to enhance your workflow, strengthen your practice, and help you deliver exceptional care with every compound.







For more information

1-800-932-1039 medisca.com.au



